Evidence map›Paper›PMID 42363945›Full record

ArticleNaunyn-Schmiedeberg's archives of pharmacology2026

Rational design of pyrazole-oxime hybrids as dual-targeting agents for glioma and breast cancer brain metastasis.

Merve Gul, Mehmet Abdullah Alagoz, Ceylan Hepokur, Oztekin Algul

Abstract read
In one paragraph

Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Merve GulDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Inonu University, Malatya, Türkiye.
Mehmet Abdullah AlagozDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Inonu University, Malatya, Türkiye. mehmet.alagoz@inonu.edu.tr.
Ceylan HepokurDepartment of Biochemistry, Faculty of Pharmacy, Sivas Cumhuriyet University, Sivas, Türkiye.
Oztekin AlgulDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Mersin University, Mersin, Türkiye.

Funding

Inönü Üniversitesi TYL-2024-3816
6 · The paper itself

Abstract

To design, synthesize, and biologically evaluate a novel series of 1-(4-chlorophenyl)-2-(4-methylpyrazol-1-yl)ethenone oxime derivatives (5-15) as targeted anticancer agents, focusing on their selectivity for glioma, mechanistic action, and blood-brain barrier (BBB) permeability. The oxime derivatives were synthesized and characterized using

Indexed as

Antineoplastic AgentsBrain NeoplasmsBreast NeoplasmsDrug DesignGliomaOximesPyrazolesAnimalsApoptosisATP Binding Cassette Transporter, Subfamily B, Member 1Blood-Brain BarrierCell Cycle CheckpointsCell Line, TumorCell ProliferationCyclin-Dependent Kinase 6FemaleAntineoplastic AgentsATP Binding Cassette Transporter, Subfamily B, Member 1CDK6 protein, humanCyclin-Dependent Kinase 6OximesPyrazolesApoptosisBreast cancerCDK6Pyrazole derivativesSAR

Identifiers

PMID42363945
PMCPMC13593641

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.